Patient-Focused Drug Development Guidance: Determining When A Clinical Outcome Assessment Is Appropriate
Executive Summary
A US FDA draft guidance on selecting and developing fit-for-purpose clinical outcome assessments specifies the evidence that can be provided to support using a COA in a particular context.
You may also be interested in...
Patient-Focused Drug Development Grants May Be Program’s ‘Most Significant’ Accomplishment Since 2019
US FDA has issued five grants for development of standard core clinical outcome assessments and related endpoints that can be used across disease areas and may produce more reliable data for regulatory decision-making.
Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons
US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.
Social Media Data Gains Prominence In Patient-Focused Drug Development
FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.